Abstract 1036P
Background
PM1003 is a VHH-based anti-PD-L1 x 4-1BB bispecific antibody that exhibits PD-L1 expression-dependent 4-1BB agonism, with excellent anti-tumor activity and safety in preclinical studies.
Methods
The safety and tolerability of PM1003 in patients (pts) with advanced solid tumors were assessed during dose escalation, and pts with advanced solid tumors positive for PD-L1 expression have been enrolled for assessing anti-tumor activity during dose expansion.
Results
At the data cut-off up to Apr. 19, 2023, 23 pts had been enrolled, with 19 pts for dose escalation (3 pts for each of the 0.02, 0.1, 1, 3, 10 mg/kg dose levels and 4 pts for the 6 mg/kg dose level). All pts had prior 1-6 lines of systemic treatment. Dose-limiting toxicity (DLT) was assessed over 21 days after the first dose followed by dosing Q2W. 4 pts were enrolled for dose expansion (2 pts in 1 mg/kg, 1 patient in each of the 3 and 6 mg/kg dose levels, Q2W). No DLTs were observed during dose escalation. Treatment-related adverse events (TRAEs) occurred in 22 pts (95.7%). The most common TRAEs in pts included anemia (39.1%, Grade≥3 0%), aspartic acid aminotransferase increased (30.4%, Grade≥3 4.3%), white blood cell count decreased (30.4%, Grade≥3 8.7%) and platelet count decreased (30.4%, Grade≥3 0%). For the 1 - 10 mg/kg cohorts, T1/2 was 6.3 - 15.3 days after the first dose. PD-L1 target occupancy approach to saturation at 7 days after the first dose and maintained stable. 18 pts were evaluable for efficacy. The objective response rate was 5.6% and the disease control rate was 44.4%. Preliminary antitumor activity was observed in one PD-L1 positive gastric cancer patient (1 mg/kg, Q2W; TPS=5%, CPS=30) who was heavily treated with chemotherapy, anti-PD-1 and anti-HER2-ADC after surgery. 87.8% of tumor shrinkage was achieved in the target lesion at the first efficacy evaluation (7 weeks) after PM1003 treatment. Partial Response was confirmed at subsequent visits.
Conclusions
PM1003 was well-tolerated at doses up to 10 mg/kg and preliminary antitumor efficacy was observed in a patient with prior anti-PD-1 treatment. Expansion cohorts to evaluate efficacy and further safety in PD-L1-positive pts are ongoing.
Clinical trial identification
ChiCTR2100052887.
Editorial acknowledgement
Legal entity responsible for the study
Biotheus Inc.
Funding
Biotheus Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19